Exhibit 3.2(bb)
"CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT
IDENTIFIED BY *** HAVE BEEN OMITTED AND HAVE BEEN SEPARATELY FILED WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS."
AGREEMENT dated September 20, 2005
BETWEEN
AUTOGEN RESEARCH PTY LIMITED(1) ABN 84 074 636 847 of Xxxxxxx Xxxx, Xxxxx Xxxxx
Xxxxxxxx 0000 ("AUTOGEN RESEARCH")
AND
INTERNATIONAL DIABETES INSTITUTE ACN 007 342 412 of 000 Xxxxxxx Xxxx, Xxxxxxxxx,
Xxxxxxxx 0000 ("IDI")
RECITALS
A. On 14 January 1998 Autogen Research (then named Autogen Pty Ltd) and
IDI entered into an agreement entitled Research, Licence and
Commercialisation Agreement ("RESEARCH AGREEMENT FOR HUMAN DIABETES /
OBESITY DISCOVERY") setting out the terms and conditions for research
to be carried out with the participation of the parties.
B. The parties now agree to extend the Research Agreement subject to the
terms and conditions of this Agreement.
AGREEMENT
1. EXTENSION OF TERM
With effect on and from 1 July 2005 the parties agree that the term of
the Research Agreement is extended until 31 December 2005 ("EXTENDED
TERM") (unless the Research Agreement is earlier terminated in
accordance with its terms). During the Extended Term the terms and
conditions of the Research Agreement will continue to apply except to
the extent to which they are inconsistent with anything set out in this
Agreement, in which case the provisions of this Agreement will prevail
to the extent of the inconsistency.
2. PAYMENT AND RESEARCH PROPOSAL DURING EXTENDED TERM
During the Extended Term:
(a) the budget set out in Schedule 1 to this Agreement will be
substituted for any payment program previously applying under
the Research Agreement; and
--------
(1) Autogen Research Pty Ltd is a wholly-owned subsidiary of ChemGenex
Pharmaceuticals Limited (ABN 79 000 248 304).
(b) the research plan (including any milestones set out therein)
set out in Schedule 2 to this Agreement will be substituted
for any research proposal and workplans previously applying
under the Research Agreement.
EXECUTED AS AN AGREEMENT
SIGNED FOR AND BEHALF of )
AUTOGEN RESEARCH PTY )
LIMITED ABN 84 074 636 847 )
..................................
Director
SIGNED FOR AND BEHALF of )
INTERNATIONAL DIABETES )
INSTITUTE ACN 007 342 412 )
.................................. ......................................
Secretary Director
2
SCHEDULE 1: BUDGET - INTERNATIONAL DIABETES INSTITUTE
ITEM 1: COMMENCEMENT DATE JULY 1, 2005
ITEM 2: TOTAL BUDGET FOR THE PERIOD OF JULY 1, 2005 TO DECEMBER 31, 2005 IS
AUD$***.
Funding consists of quarterly payments of $*** plus GST. The first payment will
be made by July 31 2005. Subsequent payments will be made upon satisfactory
completion of the performance reviews required under clause 5 of the Research
Agreement, those performance reviews (for the avoidance of doubt) to be
completed by the following dates -
o 31 October, 2005
IDI is required to forward the reviews to Autogen and following satisfactory
performance, IDI will then invoice Autogen for quarterly payment of research in
advance.
PERSONNEL:
Xxxxxx Xxxxxx Ph.D PI 100% $***
Xxxxxxxxx Xxxxxxx Ph.D Co-I 100% $***
Xxxxxx Xxxxxxxxxx BSc Xxxx XX 100% $***
Xxxxxxx Xxxx BSc RA 100% $***
Xxxxxx Xxxx BSc Xxxx XX 100% $***
Hoki Beckham-Sionetali Office Manager 60% $***
Total $***
SUPPLIES:
Equipment Maintenance Contracts (Freezers, ABI, Sqnm) $***
Laboratory Supplies $***
Total $***
EQUIPMENT:
None Required $0
TOTAL PERSONNEL, SUPPLIES AND EQUIPMENT: $***
Indirect Costs: $***
GRAND TOTAL: $*** AU
3
SCHEDULE 2: PROJECT
INTERNATIONAL DIABETES INSTITUTE
RESEARCH AIMS:
1. IDENTIFY NOVEL DIABETES & OBESITY GENES USING QTL DISSECTION.
We plan to complete if possible the dissection and identification novel
druggable genes within each of three QTLs that we have been working on over the
last 3 years. To maximise commercial benefits to ChemGenex, each QTL's snpscan
shall be limited to druggable targets only, once completed, no further work will
be undertaken on a QTL.
QTLS
o ***
o ***
o ***
QTL CURRENTLY IN PROGRESS TASK MILESTONES
-------------------------------------------------------------------------------------------------------------
*** *** druggable genes, 137/147 snps completed (St4) Complete *** SNPs and rpts June (KS)
Cohort typing of assoc snps September (KS)
*** druggable genes, complete pending *** data (St5) Select & type SNPs December (TBA)
-------------------------------------------------------------------------------------------------------------
*** *** druggable genes (80) and cSNPs (125), 205 snps Complete *** druggable September (JW)
total (St6) SNPs
-------------------------------------------------------------------------------------------------------------
*** *** druggable genes (31) and cSNPs (198), 229 snps Complete *** druggable August (AE)
total (St6) SNPs
-------------------------------------------------------------------------------------------------------------
4
2. IDENTIFICATION OF A NOVEL DIABETES GENE FROM A SELECTED QTL
There are currently *** candidate genes that we have identified as having the
potential to contribute to the 3 linkage signals under investigation. It will be
of benefit for ChemGenex to pursue the identification of ONE of these with a
view to presentation of the results at International scientific conferences and
publication in a high impact journal. This would be expected to establish
credibility and recognition for ChemGenex's human genomics gene discovery
program and may facilitate future investment in the program.
While it is preferable that the pursued candidate is druggable, the candidate
with the strongest evidence to date is *** (AGT505) with 4 statistically
significant and independent associations with FPG on *** Therefore this
candidate will be further analysed, while all others placed on hold following
completion of the initial investigation.
Designated regions most likely to be functional (exons, putative promoter,
conserved flanking and intronic segments) within AGT505 will be resequenced in
50 individuals. Novel SNPs will be genotyped in the entire cohort (n=450) and
assessed for association with FPG.
Candidate Genes
-----------------------------------------------------------------------------------------------------------------------------------
GENE QTL FUNCTION IP DATA TASKS TO COMPLETE MILESTONES
-----------------------------------------------------------------------------------------------------------------------------------
*** *** put. receptor assoc protein CXS 4 sig ind assoc Type assoc in cohort June (KS)
Seq gene for novel snps October (KG, AE,
KS, JW)
Type novel snps December (TBA)
-----------------------------------------------------------------------------------------------------------------------------------
*** *** ion channel CXS 1 sig indep assoc Hold
-----------------------------------------------------------------------------------------------------------------------------------
*** *** ? hydrolase (goa) TBD 1 sig indep assoc type in cohort (1), 1 July, Hold
in St6
-----------------------------------------------------------------------------------------------------------------------------------
*** *** ? GTPase (goa) TBD 1 sig indep assoc 3 snps current (St6) July, Hold
-----------------------------------------------------------------------------------------------------------------------------------
*** *** nuclear receptor coactivator TBD 1 sig indep assoc type assoc in cohort (4) July, Hold
(NOR1)
-----------------------------------------------------------------------------------------------------------------------------------
*** *** protease TBD 1 sig indep assoc type assoc in cohort (3) July, Hold
-----------------------------------------------------------------------------------------------------------------------------------
*** *** S/T kinase TBD 1 sig indep assoc type assoc in cohort (1) July, Hold
--------------- -------- --------------------------------- ------ ------------------ ------------------------- --------------------
TBD - To be determined
5
